Skip to main content
Premium Trial:

Request an Annual Quote

Robert Strausberg, Craig Venter, Eric Eisenstadt, Marv Frazier, Julie Gross Adelson, Aimee Turner, David Urdal, Mark Gabrielson, Jules Blake, Robert Stanley, Patricia Rougeau

Robert Strausberg has been named deputy director of the J. Craig Venter Institute as part of a broad reorganization of its two research divisions — the Institute for Genomic Research and the Center for the Advancement of Genomics — into several more tightly focused units.
The JCVI will now consist of 10 distinct research groups: Genomic Medicine, Infectious Disease, Synthetic Biology & Bioenergy, Plant Genomics, Microbial & Environmental Genomics, Pathogen Functional Genomics, Applied Bioinformatics, Research Informatics, Software Engineering, and a Policy Center.
Craig Venter will remain president and chairman of the institute, and Strausberg, who had been president of TCAG, has been named deputy director. Eric Eisenstadt, former vice president for research of TIGR, has been named deputy vice president for research.
Marv Frazier, former vice president for research at TCAG, is now the executive vice president for research. Julie Gross Adelson has been named general counsel, while Aimee Turner, formerly CFO at TIGR, is now CFO of the JCVI.

Gene Logic has elected David Urdal and Mark Gabrielson to its board of directors.
Urdal is currently senior vice president and chief scientific officer of Dendreon, while Gabrielson is a co-founder, director, and CEO of Pulmatrix.
In addition, the company said that Jules Blake is retiring from the board of directors after serving on the board since 1994.

IO Informatics has tapped Robert Stanley as president and CEO. Stanley is a company co-founder and was formerly chief technology officer at IO Informatics.
Stanley replaces former CEO Patricia Rougeau, who left the firm at the end of March.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.